TWNK stock was delisted from NASDAQ on
Nov 6, 2023. You can explore more stocks from
Consumer Defensive sector on this page.
AGIO Agios Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: AGIO
Price (delayed)
$36.07
Market cap
$2.09B
P/E Ratio
3.09
Dividend/share
N/A
EPS
$11.69
Enterprise value
$2.06B
Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In
Highlights
The quick ratio has soared by 55% since the previous quarter and by 47% year-on-year
The revenue has grown by 26% year-on-year
Agios Pharmaceuticals's equity has surged by 97% YoY but it has decreased by 4.8% QoQ
The gross margin is down by 2.8% year-on-year
Key stats
What are the main financial stats of AGIO
Market
Valuations
Earnings
Shares outstanding
57.92M
Market cap
$2.09B
Enterprise value
$2.06B
Price to earnings (P/E)
3.09
Price to book (P/B)
1.41
Price to sales (P/S)
55.96
EV/EBIT
2.9
EV/EBITDA
2.84
EV/Sales
55.7
Revenue
$37.04M
Gross profit
$32.41M
Operating income
$448.84M
Net income
$665.99M
EBIT
$710.23M
EBITDA
$727.56M
Free cash flow
-$403.77M
Per share
Balance sheet
Liquidity
EPS
$11.69
EPS diluted
$11.24
Free cash flow per share
-$7.03
Book value per share
$25.6
Revenue per share
$0.64
TBVPS
$27.07
Total assets
$1.56B
Total liabilities
$88.99M
Debt
$52.94M
Equity
$1.47B
Working capital
$916.25M
Debt to equity
0.04
Current ratio
18.5
Quick ratio
17.12
Net debt/EBITDA
-0.04
Margins
Efficiency
Dividend
EBITDA margin
1,964.5%
Gross margin
87.5%
Net margin
1,798.3%
Operating margin
1,211.9%
Return on assets
46.1%
Return on equity
50.3%
Return on invested capital
54.5%
Return on capital employed
47.2%
Return on sales
1,917.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AGIO stock price
How has the Agios Pharmaceuticals stock price performed over time
Intraday
2.04%
1 week
7.19%
1 month
8.09%
1 year
-14.16%
YTD
9.77%
QTD
8.45%
Financial performance
How have Agios Pharmaceuticals's revenue and profit performed over time
Revenue
$37.04M
Gross profit
$32.41M
Operating income
$448.84M
Net income
$665.99M
Gross margin
87.5%
Net margin
1,798.3%
The operating margin has surged by 191% year-on-year but it has declined by 4.6% since the previous quarter
The revenue has grown by 26% year-on-year
Agios Pharmaceuticals's gross profit has increased by 23% YoY
Agios Pharmaceuticals's operating income has decreased by 3.1% from the previous quarter
Price vs fundamentals
How does AGIO's price correlate with its fundamentals
Growth
What is Agios Pharmaceuticals's growth rate over time
Valuation
What is Agios Pharmaceuticals stock price valuation
P/E
3.09
P/B
1.41
P/S
55.96
EV/EBIT
2.9
EV/EBITDA
2.84
EV/Sales
55.7
Agios Pharmaceuticals's equity has surged by 97% YoY but it has decreased by 4.8% QoQ
The P/B is 33% below the 5-year quarterly average of 2.1 and 26% below the last 4 quarters average of 1.9
The revenue has grown by 26% year-on-year
AGIO's P/S is 11% below its last 4 quarters average of 63.0
Efficiency
How efficient is Agios Pharmaceuticals business performance
AGIO's return on equity is down by 15% since the previous quarter
The company's return on invested capital fell by 15% QoQ
The ROA has contracted by 13% from the previous quarter
Agios Pharmaceuticals's return on sales has decreased by 2.5% QoQ
Dividends
What is AGIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AGIO.
Financial health
How did Agios Pharmaceuticals financials performed over time
The total assets has surged by 83% year-on-year but it has declined by 6% since the previous quarter
The quick ratio has soared by 55% since the previous quarter and by 47% year-on-year
The debt is 96% smaller than the equity
Agios Pharmaceuticals's equity has surged by 97% YoY but it has decreased by 4.8% QoQ
The debt to equity has shrunk by 56% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.